These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23861604)

  • 1. Impact of denosumab on bone mass in cancer patients.
    Brown-Glaberman U; Stopeck AT
    Clin Pharmacol; 2013; 5():117-29. PubMed ID: 23861604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.
    Steger GG; Bartsch R
    Ther Adv Med Oncol; 2011 Sep; 3(5):233-43. PubMed ID: 21957430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
    Takahashi S
    Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for cancer-related bone loss.
    Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
    Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy with bone-targeted agents.
    Wilson C; Coleman RE
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab: in cancer treatment-induced bone loss.
    Muir VJ; Scott LJ
    BioDrugs; 2010 Dec; 24(6):379-86. PubMed ID: 21043545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer: Rank Ligand Inhibition.
    Bartsch R; Steger GG; Gnant M; Ziebermayr R
    Breast Care (Basel); 2010; 5(5):320-325. PubMed ID: 21779214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials.
    Galvano A; Scaturro D; Badalamenti G; Incorvaia L; Rizzo S; Castellana L; Cusenza S; Cutaia S; Santini D; Guadagni F; Roselli M; Gori S; Latteri MA; Bazan V; Giulia LM; Russo A
    J Bone Oncol; 2019 Oct; 18():100252. PubMed ID: 31440444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal health in breast cancer survivors.
    Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
    Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab in osteoporosis and oncology.
    Burkiewicz JS; Scarpace SL; Bruce SP
    Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
    Brown-Glaberman U; Stopeck AT
    Biologics; 2012; 6():89-99. PubMed ID: 22532777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer Treatment-Induced Bone Loss(CTIBL)].
    Fukumoto S; Matsumoto T
    Gan To Kagaku Ryoho; 2018 Dec; 45(12):1685-1689. PubMed ID: 30587719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-treatment-induced bone loss, part 2.
    Michaud LB; Goodin S
    Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.
    Scott LJ; Muir VJ
    Drugs; 2011 May; 71(8):1059-69. PubMed ID: 21668042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.